The hallmarks of aging · The body's responses

Senescent cells

Scientific name: Cellular senescence

When a cell is badly damaged, it can stop dividing for good instead of dying. These senescent cells stay in the tissue, build up with age, and release inflammatory signals that harm the cells around them.

Measurable today: no reliable test. Blood panels sold for it read signals that other cells also make.

Why it matters

Why it matters to you

They do harm by staying, not by dividing.

A few senescent cells can affect a whole tissue, because their signals inflame neighbors and can push nearby cells to become senescent too.

Removing them helped old mice.

In mice, a genetic switch that removed senescent cells from middle age on extended median lifespan, delayed tumors, and slowed age-related decline in kidney, heart, and fat.

Source: PubMed 26840489

They also do useful work.

Senescence stops damaged cells from turning into cancer and helps wounds heal. The aim of research is fewer lingering cells, not none.

Measurement

Can it be measured?

Blood panels of senescence signals

Some specialty labs

What it showsLevels of inflammatory proteins that senescent cells release, such as IL-6.

LimitsOther cells release the same proteins, so a result is not a count of senescent cells. There are no agreed ranges.

Research blood scores and immune-cell markers

Research only

What it showsCombined scores built from many blood proteins, or levels of the marker p16 in immune cells, used to estimate senescent-cell burden in studies.

LimitsThese are research tools still being validated, and blood may not reflect what is happening in a given organ.

Tissue staining in biopsies

Research only

What it showsSenescent cells seen directly in a tissue sample, using stains and markers.

LimitsIt needs a biopsy, covers only the sampled spot, and no single marker identifies every senescent cell.

What would make it measurable

  • A validated blood test for senescent-cell burden.
  • Imaging that shows where senescent cells build up in the body.
  • Trials showing that lowering senescent cells improves health in people.
What can be done

What can be done about it?

One item in our catalog has human studies that support an effect on senescent cells. Drugs and supplements aimed at clearing these cells are called senolytics. The first human trials have been small and short, and none has shown that clearing senescent cells slows aging in people.

Three examples from our catalog, rotated daily: one with stronger evidence here, one with early evidence, and one where we found none. A sample, not a ranking or a recommendation. Ratings as of October 25, 2026. What the evidence levels mean.

Botanical

Quercetin

Evidence for senescent cells: Supported

Human studies support it engaging this aging driver, short of the strongest trial designs.

Vitamins & Minerals

Vitamin D3

Evidence for senescent cells: Emerging

Only early or animal-stage evidence for this aging driver so far.

Amino Acids & Derivatives

Citicoline

Evidence for senescent cells: None found

We did not find qualifying evidence that it engages this aging driver.

We have not found strong evidence for it in any aging driver yet.

See the full picture for your own routine

The Longevity Intelligence Report shows how what you take and do covers senescent cells and the other hallmarks. Members also see every item in our catalog ranked by the strength of its evidence for senescent cells. Opens in December.

Get early access
New research

New studies on senescent cells

Picked for what they add to the biology, and to the chance of one day treating it, in plain words. Research checked October 17, 2026.

Senescent cells

A blood score for senescent-cell signals predicted death risk and shifted with exercise

People, UK Biobank participants, plus an 18-month exercise trial · Aging Cell · October 1, 2026

What they foundResearchers built a score from blood proteins that senescent cells release. It predicted death and new serious conditions such as dementia, heart attack, and stroke, and it changed course over 18 months of mixed exercise in a trial group.

What it does not showThe score reads signals, not senescent cells themselves, and it is a research tool, not a test you can order.

Why it mattersA reliable blood measure is the missing piece for testing whether any treatment lowers senescent-cell burden in people.

Read the study on PubMed ↗
A Deep-Learning Based Biomarker of Systemic Cellular Senescence Burden to Predict Mortality and Health Outcomes.
Senescent cells

Helping immune cells clear worn-out white blood cells slowed organ aging in mice

Mice, plus human tissue samples · Science · July 16, 2026

What they foundWith age, immune cells in tissues lose their ability to clear aged, senescent white blood cells. Turning down one signal in those immune cells kept old mice from developing frailty, muscle loss, memory decline, and heart problems.

What it does not showMice only. The blocking drug is experimental, and turning down this signal could have other effects.

Why it mattersIt suggests part of the problem is the body's cleanup failing, not only senescent cells forming, which opens a different kind of target.

Read the study on PubMed ↗
Restored clearance of senescent neutrophils by tissue-resident macrophages limits organ aging.
Senescent cells

A widely studied senolytic drug pair changed many tissues in old mice, more when started early

Mice · Nature Aging · June 17, 2026

What they foundOld mice given dasatinib plus quercetin showed better immune function, less tissue inflammation, and better metabolism. Starting earlier and treating longer worked better than a short course late in life.

What it does not showMice only. The authors note the pair clears senescent cells incompletely and can affect blood cells.

Why it mattersIt maps where this drug pair acts and where it falls short, which human trials will need to know.

Read the study on PubMed ↗
Profiling the molecular and physiological effects of senolytic treatment on aged mice identifies immune, fibrotic and metabolic remodeling.

Follow the research on senescent cells

Pick the ones you want to follow. Starting in December, we'll email you every two weeks when new studies or new tests come out on them. Longevity Intelligence Report members also get the plain-English read on each one: why it matters, and whether it should change what you're doing.

Free, no account needed. We keep your email and the topics you pick, nothing else. Unsubscribe anytime.

From the articles

Articles on senescent cells

Go deeper

Connected hallmarks

How the biology works

A cell becomes senescent when it hits a stress it cannot recover from: critically short telomeres (the protective caps on chromosomes), heavy DNA damage where even a single unrepaired double-strand break can be enough, a cancer-driving mutation, mitochondrial failure, or the stress of cancer treatment. The cell then stops dividing for good but stays alive and active, and it resists the normal self-destruct program (apoptosis) that would otherwise clear a damaged cell (PMID 24848057; PMID 33328614).

Two molecular brakes lock the cell out of the division cycle. One runs through the damage-sensor protein p53 and a stop protein called p21; the other runs through a separate stop protein called p16 (made at the CDKN2A gene) acting on the master cell-cycle gatekeeper RB. Once engaged, this arrest is durable and resists the usual signals to divide (PMID 23140366; PMID 26646499; PMID 33328614).

The arrested cell then switches on the senescence-associated secretory phenotype, or SASP: the inflammatory, tissue-remodeling cocktail of signals it broadcasts, including interleukins such as IL-6 and IL-8, chemokines, and matrix-remodeling enzymes. This is how a small number of senescent cells can have an outsized, spreading effect. The SASP drives chronic low-grade inflammation, degrades surrounding tissue, and can even push healthy neighbors into senescence. Roughly 40 percent of SASP factors are also age-associated in human blood (PMID 33262144; PMID 23140366; PMID 29988130).

In youth the SASP recruits immune cells that find and clear senescent cells. With age this immune surveillance weakens, so the cells persist and accumulate, and their secretions tip nearby healthy cells into senescence too, creating a self-reinforcing zone of dysfunction (PMID 33262144).

There is no single kind of senescent cell. The state varies markedly by tissue, cell type, and trigger, and no single marker is both sensitive and specific for it. That heterogeneity is not a footnote: it limits every biomarker and every intervention claim on this page (PMID 35599179; PMID 38831121).

Where treatment research is heading
Next few years

First-generation senolytics: dasatinib plus quercetin

The cancer drug dasatinib paired with the plant compound quercetin is the most-studied senolytic in people. In a 14-person open-label lung-fibrosis study, physical measures improved, including about a 21-meter gain in 6-minute walking distance. In a 9-person diabetic-kidney-disease study, a single short course reduced senescent (p16-positive) cells in fat tissue by about a third, the first direct human evidence that these cells can be cleared (PMID 30616998; PMID 31542391).

Not ready yet: The trials are tiny and mostly uncontrolled, and the honest headline is the best-designed one: a 60-woman randomized trial in postmenopausal bone missed its primary endpoint (PMID 38956196). In a small Alzheimer's trial, quercetin, half the famous pair, was never detected in the brain fluid at all (PMID 37679434). Dasatinib also carries real side effects, and no large trial has shown the combination improves healthspan rather than moving a marker.

Fisetin as a candidate natural senolytic

Fisetin, a flavonoid found in strawberries and other plants, is the compound most often marketed as a natural senolytic, and it is being tested in human frailty and osteoarthritis trials because its safety margin looks more favorable than the prescription drugs.

Not ready yet: The potency behind that reputation comes from cell and mouse experiments, not human results. A human pharmacokinetic trial found fisetin is poorly absorbed by mouth and rapidly broken down, so a normal capsule may never reach the levels that worked in the lab, and no human trial has yet shown it clears senescent cells or improves health in people (PMID 36304817).

Further out

Senomorphics: quieting the SASP instead of killing the cell

Rather than clearing senescent cells, senomorphics aim to silence their inflammatory broadcast. Drugs that dampen the SASP, including mTOR inhibitors such as rapamycin and JAK inhibitors, could blunt the tissue damage while avoiding the risk of killing cells the body may still need.

Not ready yet: Chronic immune-modulating drugs carry infection and side-effect risks, the best targets within the SASP are still being mapped, and long-term aging benefit in humans is unproven.

Targeted senolytic drugs such as navitoclax

Navitoclax and related BCL-2-family inhibitors block the survival proteins senescent cells depend on, and they clear these cells efficiently in preclinical models, which is why they anchor much of the drug-development effort.

Not ready yet: Their effect comes with dose-limiting toxicity, including a drop in blood platelets, which constrains how they can be used in people, and human anti-aging efficacy has not been established (PMID 32686219; PMID 37548098).

A blood test for senescent-cell burden

Academic groups are building circulating SASP panels that could, for the first time, let a trial or an individual see whether a senolytic is doing anything. In one large cohort a multi-protein senescence panel tracked with future mobility disability, and refined assays are moving toward standardization (PMID 37948612; PMID 39823170).

Not ready yet: No panel is validated or standardized for personal use, and a change in a blood signal does not equal clearing senescent cells in tissue. The one human study that checked found the marketed first-generation aging clocks moving the wrong way after a senolytic, with no control group (PMID 38393697).

Long shots

Tissue-precise, on-demand senescent-cell clearance

The long-term vision is to remove senescent cells from specific tissues, such as arthritic joints or fibrotic lungs, on a schedule, while sparing the senescent cells that help wounds heal. Genetic mouse models that flip a switch to delete these cells have already reversed several features of aging, which is the proof of concept driving the whole field (PMID 26840489).

Not ready yet: Turning a genetic kill-switch into a safe, targeted, repeatable human therapy needs delivery precision and senescence-specific targeting that do not exist yet, and no human lifespan or healthspan benefit has been demonstrated at all so far (PMID 29988130; PMID 38956196).

Facts and sources on this page checked October 17, 2026. This page explains research. It is not medical advice or a recommendation to take anything. How we grade the evidence.